Preprint · OA
via Europe PMC
Semaglutide reduces proteomic organ-specific biological age across randomized clinical trials
Dermit M, Colhoun HM, Goeminne LJE, Ryan D, Adelborg K, Belmont-Rausch D, Kolnes KJ, Knop FK, Voisin SAC, Gladyshev VN, Knudsen LB, Orozco AA.
· 2026
Abstract
<title>Abstract</title> <p>Semaglutide confers cardiovascular and kidney benefits and reduces all-cause mortality in high-risk populations. Whether biological-age metrics capture these effects and provide mechanistic insight remains unclear. We analyzed proteomics from 10,052 participants across five placebo-controlled semaglutide trials using externally trained organ-specific mortality clocks, proteomic frailty scores and disease-risk models. Semaglutide reduced heart biological age by approximately 2 to 4 years versus placebo, with reductions of 1 to 4 years across kidney, brain, pancreas, lung and multiorgan clocks. Proteomic frailty and cardiometabolic disease-risk scores improved during up to 156 weeks of follow-up. Effects were not fully mediated by weight loss, glycated hemoglobin or C-reactive protein. Exploratory mediation analyses suggested that heart biological-age changes may account for 34% to 49% of effects on selected outcomes. These findings demonstrate reproducible remodeling of mortality-associated proteomic signatures across populations and durations, supporting their potential as treatment-response readouts without establishing biological rejuvenation, causal mediation or surrogate validity.</p>
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.21203/rs.3.rs-11082091/v1
- Canonical
- link ↗
- Fetched
- 2026-10-09 MST
Cite this
APA
M, D., HM, C., LJE, G., D, R., K, A., D, B., KJ, K., FK, K., SAC, V., VN, G., LB, K., & AA., O. (2026). Semaglutide reduces proteomic organ-specific biological age across randomized clinical trials. https://doi.org/10.21203/rs.3.rs-11082091/v1
Vancouver
M D, HM C, LJE G, D R, K A, D B, et al. Semaglutide reduces proteomic organ-specific biological age across randomized clinical trials. 2026. doi:10.21203/rs.3.rs-11082091/v1.
BibTeX
@unpublished{dermit2026Semagl,
title = {Semaglutide reduces proteomic organ-specific biological age across randomized clinical trials},
author = {Dermit M and Colhoun HM and Goeminne LJE and Ryan D and Adelborg K and Belmont-Rausch D and Kolnes KJ and Knop FK and Voisin SAC and Gladyshev VN and Knudsen LB and Orozco AA.},
year = {2026},
doi = {10.21203/rs.3.rs-11082091/v1},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Research Square 2026
Preprint · CC-BY
Semaglutide reduces proteomic organ-specific biological age across randomized clinical trials
Nutrition & Metabolism 2026
Open access · CC-BY
The caffeine spectrum: associations of intake, metabolites, and metabolite ratios with biological aging acceleration, frailty and mortality
bioRxiv (Cold Spring Harbor Laboratory) 2026
Preprint · CC-BY
Intraindividual longitudinal changes of the proteome reveal dynamic markers of biological aging
Nature Aging 2026
Open access · CC-BY
Associations of proteomic age clocks with lifestyle risk factors, incident chronic diseases and mortality in two European cohorts
Nature aging 2026
Open access · OA
Associations of proteomic age clocks with lifestyle risk factors, incident chronic diseases and mortality in two European cohorts.
2026
Preprint